Description
Market Report Coverage – Preimplantation Genetic Testing
Market Segmentation
• Product Type – Reagents and Consumables, Kits and Services
• Application – Structural Chromosomal Abnormalities, Single Gene Disorder and Others
• Technology – Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), In Situ Hybridization (ISH/FISH), Microarray
• End User – Diagnostic Center, Research Center, and Others
Regional Segmentation
• North America – U.S., Canada
• Europe – France, Italy, U.K., Spain, Netherlands, Russia, and Rest-of-Europe
• Asia-Pacific – China, Japan, India, South Korea, Australia, and Rest-of-Asia-Pacific (RoAPAC)
• Rest-of-the-World
Market Growth Drivers
• Advancing Maternal Age Globally
• A Rise in Adoption of In-Vitro Fertilization
• Increasing Awareness for Genetic Testing
• Rising Emphasis on Predictive Genetic Testing for Early Detection
Market Challenges
• Ethical Issues Pertaining to the Preimplantation Genetic Testing
• High Procedural Cost Associated with Preimplantation Genetic Testing
Market Opportunities
• Decreasing Cost of Genomic Sequencing
• The Emergence of Reproductive Tourism
Key Companies Profiled
Abbott Laboratories, Agilent Technologies, Inc., BGI, Fulgent Genetics, Inc., Igenomix, Illumina, Inc., Invitae Corporation, Myriad Genetics, Inc., MedGenome Labs Ltd., Natera, Inc., PerkinElmer, Inc., Pac Genomics, Thermo Fisher Scientific Inc.
Key Questions Answered in this Report:
• What are the factors necessitating the requirement of global preimplantation genetic testing globally?
• What are the different types of products available in the global preimplantation genetic testing market?
• What are the key development strategies implemented by the key players to stand out in this global preimplantation genetic testing market?
• What are the various technologies deployed within the global preimplantation genetic testing market?
• How have the strategic collaborations among the key players provided a push to product development within the global preimplantation genetic testing market?
• Which are the leading companies that are dominating the global preimplantation genetic testing market?
• Based on the application type, which therapy in the global preimplantation genetic testing market is anticipated to witness a massive rise in demand during the forecast period?
• How is each segment of the global preimplantation genetic testing market expected to grow during the forecast period, and what revenue will be generated by each segment by the end of 2031?
Market Overview
Preimplantation genetic diagnosis (PGD) is performed among couples that have a higher risk of transmitting a genetic condition to their offspring. The technique is employed in in-vitro fertilization centers globally to select the euploid embryos to transfer and improve the clinical outcome of the clinical pregnancy, embryo implantation, and live birth rates.
The ability to identify the preimplantation embryos with the genetic defects prior to the initiation of the pregnancy also offers an attractive alternative to chorionic villous sampling or amniocentesis.
The preimplantation genetic testing is set to grow at a significant rate in the upcoming years as the technology and awareness regarding the test improve.
The global preimplantation genetic testing market was valued at $972.1 million in 2020 and is expected to reach $2,725.7 million by 2031, registering a CAGR of 9.69% during the forecast period 2021-2031.
The growth is attributed to the advancing maternal age globally, rising adoption of in-vitro fertilization, increasing awareness of genetic testing, and rising emphasis on predictive testing. Further, continued significant investments by biotechnology firms to improve the technology for genetic testing and to improve affordability have also promoted the prominence of preimplantation genetic testing.
Within the research report, the market is segmented based on product, application, end user, technology, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.
Competitive Landscape
The exponential rise in the usage of in-vitro fertilization facilities as an option for healthy childbirth and increasing affordability for genetic testing on a global level has created awareness as well as demand among consumers, which has eventually led to the companies to invest in the development of more such preimplantation genetic test.
The companies such as Agilent Technologies, Inc. and Natera, Inc. have been incorporating major strategies to enhance their market presence via key developments. The other major contributors to the market include companies such as Thermo Fisher Scientific, PerkinElmer, Inc., Invitae Inc., and Igenomix.
Based on region, North America holds the largest share of the preimplantation genetic testing market due to eased regulatory scenario and a large number of IVF facilities offering such PGT tests.
Further, substantial investments made by biotechnology companies to improve the genetic testing facilities and advancing technologies along with the rise in per capita income in the region are also fuelling the growth of the respective market. Apart from this, the Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period.
Global Adult Hemoglobinopathy Testing Market 2029
Table of Contents
1 Product Definition
2 Research Methodology
1.1 Primary Data Sources
1.2 Secondary Data Sources
1.3 Market Estimation Model
3 Market Overview
3.1 Introduction
3.2 Market Footprint
3.3 Impact of Preimplantation Genetic Testing on Pregnancy Outcomes
3.4 Impact of COVID-19 Pandemic on Global Preimplantation Genetic Testing Market
3.5 COVID-19 Affecting Supply Chain of Global Preimplantation Genetic Testing Market
3.6 Interruption in Research and Clinical Development and Commercial Operation
3.6.1 Research and Clinical Development
3.6.2 Commercial Operation and Access
3.7 Navigating Crisis Recovery and Looking to the Future
4 Market Dynamics
4.1 Overview
4.2 Market Driving Factors
4.2.1 Advancing Maternal Age Globally
4.2.2 A Rise in Adoption of In-Vitro Fertilization
4.2.3 Increasing Awareness for Genetic Testing
4.2.4 Rising Emphasis on Predictive Genetic Testing for Early Detection
4.3 Market Restraining Factors
4.3.1 Ethical Issues Pertaining to the Preimplantation Genetic Testing
4.3.2 High Procedural Cost Associated with Preimplantation Genetic Testing
4.4 Market Opportunities
4.4.1 Decreasing Cost of Genomic Sequencing
4.4.2 The Emergence of Reproductive Tourism
5 Industry Analysis
5.1 Legal and Regulatory Framework
5.1.1 Regulatory Framework in the U.S.
5.1.2 Regulatory Framework in Europe
5.1.2.1 U.K.
5.1.2.2 France
5.1.2.3 Italy
5.1.3 Regulatory Framework in Asia-Pacific
5.1.3.1 Japan
5.1.3.2 China
5.2 Patent Landscape
6 Competitive Landscape
6.1 Overview
6.2 Key Developments and Strategies
6.3 New Offerings
6.4 Partnerships
6.5 Mergers and Acquisition
6.6 Market Share Analysis, by Company
7 Global Preimplantation Genetic Testing Market, by Product, 2020-2031, $Million
7.1 Overview
7.2 Reagents and Consumables
7.3 Kits
7.4 Services
8 Global Preimplantation Genetic Testing Market, by Application, 2020-2031, $Million
8.1 Aneuploidy
8.2 Structural Chromosomal Abnormalities
8.3 Single Gene Disorder
8.4 Others
9 Global Preimplantation Genetic Testing Market, by End User, 2020-2031, $Million
9.1 Overview
9.2 Diagnostic Center
9.3 Research Center
9.4 Others
10 Global Preimplantation Genetic Testing Market, by Technology, 2020-2031, $Million
10.1 Next-Generation Sequencing
10.2 Polymerase Chain Reaction
10.3 In Situ Hybridization (ISH/FISH)
10.4 Microarray
11 Global Preimplantation Genetic Testing Market, by Region, 2020-2031, $Million
11.1 Overview
11.2 North America
11.2.1 North America: Market Dynamics
11.2.2 U.S.
11.2.3 Canada
11.3 Europe
11.3.1 Europe: Market Dynamics
11.3.2 U.K.
11.3.3 France
11.3.4 Italy
11.3.5 Spain
11.3.6 Netherlands
11.3.7 Russia
11.3.8 Rest-of-Europe
11.4 Asia-Pacific
11.4.1 Japan
11.4.2 China
11.4.3 India
11.4.4 Australia
11.4.5 South Korea
11.4.6 Rest-of-Asia-Pacific
11.5 Rest-of-the-World
12 Company Profiles
12.1 Overview
12.2 Abbott Laboratories
12.2.1 Company Overview
12.2.2 Role of Abbott Laboratories in the Global Preimplantation Genetic Testing Market
12.2.3 Financials
12.2.4 SWOT Analysis
12.3 Agilent Technologies, Inc.
12.3.1 Company Overview
12.3.2 Role of Agilent Technologies, Inc. in the Global Preimplantation Genetic Testing Market
12.3.3 Financials
12.3.4 SWOT Analysis
12.4 BGI
12.4.1 Company Overview
12.4.2 Role of BGI Group in Global Preimplantation Genetic Testing Market
12.4.3 SWOT Analysis
12.5 Fulgent Genetics, Inc.
12.5.1 Company Overview
12.5.2 Role of Fulgent Genetics, Inc. in the Global Preimplantation Genetic Testing Market
12.5.3 Financials
12.5.4 SWOT Analysis
12.6 Igenomix
12.6.1 Company Overview
12.6.2 Role of Igenomix in the Global Preimplantation Genetic Testing Market
12.6.3 SWOT Analysis
12.7 Illumina, Inc.
12.7.1 Company Overview
12.7.2 Role of Illumina, Inc. in the Global Preimplantation Genetic Testing Market
12.7.3 Financials
12.7.4 SWOT Analysis
12.8 Invitae Corporation
12.8.1 Company Overview
12.8.2 Role of Invitae Corporation in the Global Preimplantation Genetic Testing Market
12.8.3 Financials
12.8.4 SWOT Analysis
12.9 Myriad Genetics, Inc.
12.9.1 Company Overview
12.9.2 Role of Myriad Genetics, Inc. in the Global Preimplantation Genetic Testing Market
12.9.3 Financials
12.9.4 Key Insights About Financial Health of the Company
12.9.5 SWOT Analysis
12.1 MedGenome Labs Ltd.
12.10.1 Company Overview
12.10.2 Role of MedGenome in the Global Preimplantation Genetic Testing Market
12.10.3 SWOT Analysis
12.11 Natera, Inc.
12.11.1 Company Overview
12.11.2 Role of Natera, Inc. in the Global Preimplantation Genetic Testing Market
12.11.3 Financials
12.11.4 SWOT Analysis
12.12 PerkinElmer, Inc.
12.12.1 Company Overview
12.12.2 Role of PerkinElmer, Inc. in the Global Preimplantation Genetic Testing Market
12.12.3 Financials
12.12.4 SWOT Analysis
12.13 Pac Genomics
12.13.1 Company Overview
12.13.2 Role of Pac Genomics in the Global Preimplantation Genetic Testing Market
12.13.3 SWOT Analysis
12.14 Thermo Fisher Scientific Inc.
12.14.1 Company Overview
12.14.2 Role of Thermo Fisher Scientific Inc. in the Global Preimplantation Genetic Testing Market
12.14.3 Financials
12.14.4 SWOT Analysis
List of Figures
Figure 1: Global Male and Female Infertility Trend, 2015-2019
Figure 2: Global Preimplantation Genetic Testing Market, 2020-2031
Figure 3: Market Drivers and Market Restraints
Figure 4: Share of Key Developments and Strategies, January 2017-October 2021
Figure 5: Global Preimplantation Genetic Testing Market Research Methodology
Figure 6: Primary Research Methodology
Figure 7: Bottom-Up Approach (Segment-Wise Analysis)
Figure 8: Strategies for Testing via Preimplantation Genetic Diagnosis
Figure 9: Global Preimplantation Genetic Testing Market, $Million, 2020-2031
Figure 10: Pre-COVID-19 and Post-COVID-19 Scenario, Global Preimplantation Genetic Testing Market, 2020-2025
Figure 11: Measure to Navigate Crisis Recovery
Figure 12: Global Preimplantation Genetic Testing Market Dynamics
Figure 13: Live Births Per Women, by Region (Fertility Rate)
Figure 14: IVF Cycles in Different Age-Groups (2016 and 2018)
Figure 15: Cost of Genome Sequencing
Figure 16: Number of Patents (by Year), 2016-2020
Figure 17: Share of Key Developments and Strategies, January 2017-October 2021
Figure 18: Product Offering Share (by Company), January 2017-October 2021
Figure 19: Partnership Activities Share (by Company), January 2017-October 2021
Figure 20: Mergers and Acquisitions Share (by Company), January 2017-October 2021
Figure 21: Market Share Analysis: Global Preimplantation Genetic Testing Market Share Analysis (by Company), 2020
Figure 22: Share of Global Preimplantation Genetic Testing Market, by Product, $Million, 2020-2031
Figure 23: Global Preimplantation Genetic Testing Market, Reagents and Consumables, $Million, 2020-2031
Figure 24: Global Preimplantation Genetic Testing Market, Kits, $Million, 2020-2031
Figure 25: Global Preimplantation Genetic Testing Market, Services, $Million, 2020-2031
Figure 26: Global Preimplantation Genetic Testing Market, by Application, $Million, 2020 and 2031
Figure 27: Global Preimplantation Genetic Testing Market, Aneuploidy, $Million, 2020-2031
Figure 28: Types of Structural Chromosomal Abnormalities
Figure 29: Global Preimplantation Genetic Testing Market, Structural Chromosomal Abnormalities, $Million, 2020-2031
Figure 30: Pedigree Analysis of Inheritance Pattern of a Dominant Disease
Figure 31: Pedigree Analysis of Inheritance Pattern of a Recessive Disease
Figure 32: Global Preimplantation Genetic Testing Market, Single Gene Disorder, $Million, 2020-2031
Figure 33: Global Preimplantation Genetic Testing Market, Others, $Million, 2020-2031
Figure 34: Global Preimplantation Genetic Testing Market, Diagnostic Center, $Million, 2020-2031
Figure 35: Global Preimplantation Genetic Testing Market, Research Center, $Million, 2020-2031
Figure 36: Global Preimplantation Genetic Testing Market, Others, $Million, 2020-2031
Figure 37: Share of Global Preimplantation Genetic Testing Market, by Technology, $Million, 2020-2031
Figure 38: Global Preimplantation Genetic Testing Market, Next-Generation Sequencing, $Million, 2020-2031
Figure 39: Global Preimplantation Genetic Testing Market, PCR, $Million, 2020-2031
Figure 40: Global Preimplantation Genetic Testing Market, ISH, $Million, 2020-2031
Figure 41: Global Preimplantation Genetic Testing Market, Microarray, $Million, 2020-2031
Figure 42: Global Preimplantation Genetic Testing Market (by Region)
Figure 43: North America Preimplantation Genetic Testing Market, $Million, 2020-2031
Figure 44: North America: Market Dynamics
Figure 45: North America Preimplantation Genetic Testing Market (by Country), $Million, 2020-2031
Figure 46: U.S. Preimplantation Genetic Testing Market, $Million, 2020-2031
Figure 47: Canada Preimplantation Genetic Testing Market, $Million, 2020-2031
Figure 48: Europe Preimplantation Genetic Testing Market, $Million, 2020-2031
Figure 49: Europe: Market Dynamics
Figure 50: Europe Preimplantation Genetic Testing Market (by Country), 2020 and 2031
Figure 51: U.K. Preimplantation Genetic Testing Market, $ Million, 2020-2031
Figure 52: France Preimplantation Genetic Testing Market, $Million, 2020-2031
Figure 53: Italy Preimplantation Genetic Testing Market, $Million, 2020-2031
Figure 54: Spain Preimplantation Genetic Testing Market, $Million, 2020-2031
Figure 55: Netherlands Preimplantation Genetic Testing Market, $Million, 2020-2031
Figure 56: Russia Preimplantation Genetic Testing Market, $Million, 2020-2031
Figure 57: Rest-of-Europe Preimplantation Genetic Testing Market, $Million, 2020-2031
Figure 58: Asia-Pacific Preimplantation Genetic Testing Market, $Million, 2020-2031
Figure 59: Japan Preimplantation Genetic Testing Market, $Million, 2020-2031
Figure 60: China Preimplantation Genetic Testing Market, $Million, 2020-2031
Figure 61: India Preimplantation Genetic Testing Market, $Million, 2020-2031
Figure 62: Australia Preimplantation Genetic Testing Market, $Million, 2020-2031
Figure 63: South Korea Preimplantation Genetic Testing Market, $Million, 2020-2031
Figure 64: Rest-of-Asia-Pacific Preimplantation Genetic Testing Market, $Million, 2020-2031
Figure 65: Rest-of-the-World Preimplantation Genetic Testing Market, $Million, 2020-2031
Figure 66: Shares of Key Company Profiles
Figure 67: Abbott Laboratories.: Overall Product Offerings
Figure 68: Abbott Laboratories: Overall Financials, 2017-2020
Figure 69: Abbott Laboratories: Net Revenue (by Business Segment), 2018-2020
Figure 70: Abbott Laboratories: Net Revenue (by Region), 2017-2019
Figure 71: Abbott Laboratories: Research and Development Expense, 2018-2020
Figure 72: Abbott Laboratories: SWOT Analysis
Figure 73: Agilent Technologies, Inc.: Overall Product Offerings
Figure 74: Agilent Technologies, Inc.: Overall Financials, 2018-2020
Figure 75: Agilent Technologies, Inc.: Net Revenue (by Business Segment), 2018-2020
Figure 76: Agilent Technologies, Inc.: Revenue (by Region), 2018-2020
Figure 77: Agilent Technologies, Inc.: Research and Development Expense, 2018-2020
Figure 78: Agilent Technologies, Inc.: SWOT Analysis
Figure 79: BGI Group.: Overall Product Portfolio
Figure 80: BGI Group: SWOT Analysis
Figure 81: Fulgent Genetics, Inc.: Overall Product Offerings
Figure 82: Fulgent Genetics, Inc.: Overall Financials, 2018-2020
Figure 83: Fulgent Genetics, Inc.: Net Revenue (by Region), 2018-2020
Figure 84: Fulgent Genetics, Inc.: Research and Development Expense, 2018-2020
Figure 85: Fulgent Genetics, Inc.: SWOT Analysis
Figure 86: Igenomix: Overall Product Portfolio
Figure 87: Igenomix.: SWOT Analysis
Figure 88: Illumina, Inc.: Overall Product Portfolio
Figure 89: Illumina, Inc.: Overall Financials, 2018-2020
Figure 90: Illumina, Inc.: Revenue (by Segment), 2018-2020
Figure 91: Illumina, Inc.: Revenue (by Region), 2018-2020
Figure 92: Illumina, Inc.: R&D Expenditure, 2018-2020
Figure 93: Illumina, Inc.: SWOT Analysis
Figure 94: Invitae Corporation: Overall Product Offerings
Figure 95: Invitae Corporation: Overall Financials, 2018-2020
Figure 96: Invitae Corporation: Revenue (by Segment), 2018-2020
Figure 97: Invitae Corporation: Revenue (by Region), 2018-2020
Figure 98: Invitae Corporation: R&D Expenditure, 2018-2020
Figure 99: Invitae Corporation: SWOT Analysis
Figure 100: : Myriad Genetics, Inc.: Product Portfolio
Figure 101: Myriad Genetics, Inc.: Overall Financials, 2018-2020
Figure 102: Myriad Genetics, Inc.: Revenue (by Business Segment), 2018-2020
Figure 103: Myriad Genetics, Inc.: R&D Expenditure, 2018-2020
Figure 104: Myriad Genetics, Inc.: SWOT Analysis
Figure 105: MedGenome: Overall Product Portfolio
Figure 106: MedGenome: SWOT Analysis
Figure 107: Natera, Inc.: Overall Product Offerings
Figure 108: Natera, Inc.: Overall Financials, 2018-2020
Figure 109: Natera, Inc.: R&D Expenditure, 2018-2020
Figure 110: Natera, Inc.: SWOT Analysis
Figure 111: PerkinElmer, Inc.: Overall Product Offerings
Figure 112: PerkinElmer, Inc: Overall Financials, 2018-2020
Figure 113: PerkinElmer, Inc.: Revenue (by Segment), 2018-2020
Figure 114: PerkinElmer, Inc.: R&D Expenditure, 2018-2020
Figure 115: PerkinElmer, Inc.: SWOT Analysis
Figure 116: Pac Genomics.: Overall Product Offerings
Figure 117: Pac Genomics: SWOT Analysis
Figure 118: Thermo Fisher Scientific Inc.: Overall Product Portfolio
Figure 119: Thermo Fisher Scientific Inc.: Overall Financials, 2018-2020
Figure 120: Thermo Fisher Scientific Inc.: Revenue (by Segment), 2018-2020
Figure 121: Thermo Fisher Scientific Inc.: R&D Expenditure, 2018-2020
Figure 122: Thermo Fisher Scientific Inc.: SWOT Analysis
List of Tables
Table 1: Incidence of Aneuploidies
Table 2: Global Incidence of Major Single Gene Disorders
